JNJ-95597528

DRUG3 trials

Sponsors

Janssen Cilag International, Janssen Research & Development, LLC

Conditions

AsthmaDermatitis, AtopicModerate to Severe Atopic Dermatitis

Phase 2

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Active, not recruitingNCT07230860

Janssen Research & Development, LLCDermatitis, Atopic

Start: 2026-01-20End: 2028-02-10Updated: 2026-08-28

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis

Not yet recruitingCTIS2025-523464-20-00

Janssen Cilag InternationalModerate to Severe Atopic Dermatitis

Target: 7Updated: 2026-05-19

A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma

Not yet recruitingNCT07746687

Janssen Research & Development, LLCAsthma

Start: 2026-10-29End: 2030-07-04Target: 440Updated: 2026-08-31